River Street Advisors LLC Has $3.44 Million Holdings in Eli Lilly and Company $LLY

River Street Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 26.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,510 shares of the company’s stock after purchasing an additional 947 shares during the quarter. Eli Lilly and Company accounts for 1.3% of River Street Advisors LLC’s investment portfolio, making the stock its 16th largest holding. River Street Advisors LLC’s holdings in Eli Lilly and Company were worth $3,441,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $8,827,714,000. Jennison Associates LLC raised its holdings in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after acquiring an additional 103,119 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Eli Lilly and Company Stock Down 3.6%

LLY stock opened at $1,041.78 on Tuesday. The stock has a fifty day moving average of $1,017.48 and a 200-day moving average of $853.10. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a market capitalization of $984.88 billion, a price-to-earnings ratio of 50.97, a PEG ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LLY. HSBC reissued a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Daiwa Capital Markets set a $1,230.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research report on Monday, December 1st. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Five investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $1,161.27.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.